Regular ArticleSmall Cell Carcinoma of the Cervix Treated with Concurrent Radiotherapy, Cisplatin, and Etoposide
References (0)
Cited by (55)
Invasive cervical cancer
2023, DiSaia and Creasman Clinical Gynecologic OncologyPrognostic Factors and Impact of Minimally Invasive Surgery in Early-stage Neuroendocrine Carcinoma of the Cervix
2020, Journal of Minimally Invasive GynecologyInvasive cervical cancer
2018, Clinical Gynecologic OncologyNeuroendrocrine tumors of the uterine cervix: A therapeutic challenge for gynecologic oncologists
2017, Gynecologic OncologyCitation Excerpt :Chemotherapy both in the neoadjuvant and adjuvant setting, as well as in concomitance with radiotherapy, has been more and more employed in this malignancy. The most frequently used regimens include cisplatin and etoposide (PE), vincristine, doxorubicin and cyclophosphamide (VAC), cisplatin, vincristine or vinblastine and bleomycin (PVB), cisplatin, doxorubicin and etoposide (PAE), cisplatin and 5-fluorouracil (P-FU), carboplatin and etoposide (CE), carboplatin and paclitaxel (CP), and cisplatin and irinotecan (PI) [33, 36–39, 41, 48–50, 61–62] (Table 5). In a retrospective study on 34 women with early stage SCNEC treated with radical surgery and adjuvant chemotherapy with or without radiotherapy, the 2-year OS was 38% and the use of PE and VAC regimens was associated with the better clinical outcome [33] (Table 4 and Table 5).
Small cell carcinoma of the gynecologic tract: A multifaceted spectrum of lesions
2014, Gynecologic OncologyCitation Excerpt :Concurrent chemoradiation therapy (CCRT) has been also tested in patients with SmCCx. In a clinical trial using four cycles of cisplatin plus etoposide (PE) along with pelvic radiotherapy in stage IB–IIIB SmCCx, the rate of distant and pelvic failure were 28% and 13% after long-term follow-up [14,41]. Also in the TGOG study, CCRT containing at least 5 cycles of PE was associated with an improved 5-year failure-free (62% vs 13.1%, P = 0.025) and cancer-specific survival (75.0% vs 16.9%, P = 0.016) as compared to other treatment options in stages IIB–IVB [30].